nach oben

International Urology and Nephrology

Erschienen in:

23.08.2019 | Urology - Original Paper

The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer

verfasst von: Ismail Selvi, Halil Basar, Numan Baydilli, Koza Murat, Ozlem Kaymaz

Erschienen in: International Urology and Nephrology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is still no certain threshold value of prostate-specific antigen (PSA) for prostate cancer diagnosis. We aimed to investigate the predictive value of arginine and its metabolites for diagnosing prostate cancer in patients with PSA 4–10 ng/ml and evaluate their usefulness as prognostic tumor markers.

Methods

Seventy-eight patients with a mean age of 64.50 ± 5.49 years were included in our prospective observational study between November 2016 and March 2017. They were divided into two equal groups according to the pathologic results of prostate biopsy (benign vs. malignant). Plasma arginine and ornithine levels were analyzed before biopsy by liquid chromatography–tandem mass spectrometry. ELISA was used for analyzing urinary diacetylspermine.

Results

In PSA-adjusted analysis, the malignant group had lower plasma arginine levels (p = 0.021) and arginine to ornithine ratio (AOR) (p = 0.010), but higher plasma ornithine levels (p = 0.012) and urinary diacetylspermine levels (p < 0.001) as compared with the benign group. While arginine (r = − 0.628, p < 0.001) and AOR (r = − 0.714, p < 0.001) were negatively correlated with D’Amico clinical classification (p < 0.001), ornithine (r = 0.659, p < 0.001) and diacetylspermine (r = 0.710, p < 0.001) were found to be positively correlated (p < 0.001). In multivariate analysis, ornithine [OR 3.264, 95% CI (1.045–10.196), p = 0.042] and diacetylspermine [OR 6.982, 95% CI (2.403–20.290), p < 0.001] were found to be more significant in detection of prostate cancer.

Conclusion

Plasma arginine, ornithine, AOR and urinary diacetylspermine levels may be used as molecular markers to predict prostate biopsy outcomes in patients with PSA 4–10 ng/ml. But according to our results, the use of ornithine and diacethylspermine prior to biopsy seems to be the most cost-effective diagnostic strategy.

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: Cancer J Clinicians 62(1):10–29. https://doi.org/10.3322/caac.20138 CrossRef

Loeb S, Eastham J (2016) Diagnosis and staging of prostate cancer. In: Wein AJ, Kavoussi LR (eds) Campbell—walsh urology, 11th edn. Elsevier, Philadelphia, pp 2601–2608

Barry MJ, Simmons LH (2017) Prevention of prostate cancer morbidity and mortality: primary prevention and early detection. Med Clin N Am 101(4):787–806. https://doi.org/10.1016/j.mcna.2017.03.009 CrossRefPubMed

Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A (2005) Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. BJU Int 95(4):545–548. https://doi.org/10.1111/j.1464-410X.2005.05336.x CrossRefPubMed

Cucchiara V, Cooperberg MR, Dall’Era M, Lin DW, Montorsi F, Schalken JA, Evans CP (2018) Genomic markers in prostate cancer decision making. Eur Urol 73(4):572–582. https://doi.org/10.1016/j.eururo.2017.10.036 CrossRefPubMed

Hu L, Gao Y, Cao Y, Zhang Y, Xu M, Wang Y, Jing Y, Guo S, Jing F, Hu X, Zhu Z (2016) Identification of arginine and its “Downstream” molecules as potential markers of breast cancer. IUBMB Life 68(10):817–822. https://doi.org/10.1002/iub.1557 CrossRefPubMed

Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126(12):2762–2772. https://doi.org/10.1002/ijc.25202 CrossRefPubMed

Takahashi Y, Horio H, Sakaguchi K, Hiramatsu K, Kawakita M (2015) Significant correlation between urinary N(1), N(12)-diacetylspermine and tumor invasiveness in patients with clinical stage IA non-small cell lung cancer. BMC Cancer 15:65. https://doi.org/10.1186/s12885-015-1068-5 CrossRefPubMedPubMedCentral

Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S et al (2019) European association of urology guidelines on prostate cancer: the 2019 update. EAU Guidelines Office, Arnhem, The Netherlands. ISBN 978-94-92671-04-2. http://uroweb.org/guidelines/compilations-of-all-guidelines/. Accessed 19 March 2019

10.

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P (2009) Prostate specific antigen best practice statement: 2009 update. J Urol 182(5):2232–2241. https://doi.org/10.1016/j.juro.2009.07.093 CrossRefPubMed

11.

Feng J, Gang F, Li X, Jin T, Houbao H, Yu C, Guorong L (2013) Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen. Int Urol Nephrol 45(4):1023–1028. https://doi.org/10.1007/s11255-013-0491-2 CrossRefPubMed

12.

Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA (2012) Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. BJU international 110(11 Pt B):E688–E693. https://doi.org/10.1111/j.1464-410x.2012.11501.x CrossRefPubMed

13.

Mazaris E, Tsiotras A (2013) Molecular pathways in prostate cancer. Nephro-Urol Mon 5(3):792–800. https://doi.org/10.5812/numonthly.9430 CrossRef

14.

Kelly RS, Vander Heiden MG, Giovannucci E, Mucci LA (2016) Metabolomic biomarkers of prostate cancer: prediction, diagnosis, progression, prognosis, and recurrence. Cancer Epidemiol Biomark Prev 25(6):887–906. https://doi.org/10.1158/1055-9965.EPI-15-1223 CrossRef

15.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Drager BJ, Schroder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A (2014) Prevention and early detection of prostate cancer. Lancet Oncol 15(11):e484–e492. https://doi.org/10.1016/S1470-2045(14)70211-6 CrossRefPubMedPubMedCentral

16.

DeBerardinis RJ, Thompson CB (2012) Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148(6):1132–1144. https://doi.org/10.1016/j.cell.2012.02.032 CrossRefPubMedPubMedCentral

17.

Kawakita M, Hiramatsu K (2006) Diacetylated derivatives of spermine and spermidine as novel promising tumor markers. J Biochem 139(3):315–322. https://doi.org/10.1093/jb/mvj068 CrossRefPubMed

18.

Hiramatsu K, Sakaguchi K, Fujie N, Saitoh F, Takahama E, Moriya SS, Iwasaki K, Sakaguchi M, Takahashi K, Kawaikta M (2014) Excretion of N(1), N(12)-diacetylspermine in the urine of healthy individuals. Ann Clin Biochem 51(Pt 4):459–467. https://doi.org/10.1177/0004563213496978 CrossRefPubMed

19.

Kuwata G, Hiramatsu K, Samejima K, Iwasaki K, Takahashi K, Koizumi K, Horiguchi S, Moriya SS, Kobayashi M, Kawakita M (2013) Increase of N1, N12-diacetylspermine in tissues from colorectal cancer and its liver metastasis. J Cancer Res Clin Oncol 139(6):925–932. https://doi.org/10.1007/s00432-013-1405-5 CrossRefPubMed

20.

Takahashi Y, Sakaguchi K, Horio H, Hiramatsu K, Moriya S, Takahashi K, Kawakita M (2015) Urinary N1, N12-diacetylspermine is a non-invasive marker for the diagnosis and prognosis of non-small-cell lung cancer. Br J Cancer 113(10):1493–1501. https://doi.org/10.1038/bjc.2015.349 CrossRefPubMedPubMedCentral

21.

Derezinski P, Klupczynska A, Sawicki W, Palka JA, Kokot ZJ (2017) Amino acid profiles of serum and urine in search for prostate cancer biomarkers: a pilot study. Int J Med Sci 14(1):1–12. https://doi.org/10.7150/ijms.15783 CrossRefPubMedPubMedCentral

22.

Hsueh EC, Knebel SM, Lo WH, Leung YC, Cheng PN, Hsueh CT (2012) Deprivation of arginine by recombinant human arginase in prostate cancer cells. J Hematol Oncol 5:17. https://doi.org/10.1186/1756-8722-5-17 CrossRefPubMedPubMedCentral

23.

Satoh T, Matsumoto K, Tabata K-i, Kimura M, Sato E, Hamaoki M, Baba S (2009) Urine diacetylspermine in patients with prostate cancer: association with bone turnover and metastasis. J Urol 181(4S):189. https://doi.org/10.1016/S0022-5347(09)60544-9 CrossRef

24.

Umemori Y, Ohe Y, Kuribayashi K, Tsuji N, Nishidate T, Kameshima H, Hirata K, Watanabe N (2010) Evaluating the utility of N1, N12-diacetylspermine and N1, N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers. Clinica Chimica Acta 411(23–24):1894–1899. https://doi.org/10.1016/j.cca.2010.07.018 CrossRef

25.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA (2014) Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 65(3):534–542. https://doi.org/10.1016/j.eururo.2012.11.014 CrossRefPubMed

26.

Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, Hessels D (2010) Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 58(4):475–481. https://doi.org/10.1016/j.eururo.2010.06.039 CrossRefPubMed

27.

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, Schaik RHN, Mizrahi IA (2011) A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185(5):1650–1655. https://doi.org/10.1016/j.juro.2010.12.032 CrossRefPubMedPubMedCentral

28.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ (2014) The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol 66(6):1109–1115. https://doi.org/10.1016/j.eururo.2014.08.011 CrossRefPubMedPubMedCentral

29.

Russo GI, Regis F, Castelli T, Favilla V, Privitera S, Giardina R, Cimino S, Morgia G (2017) A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-Kallikrein panel score in predicting overall and high-grade prostate cancer. Clin genitourin Cancer 15(4):429–439. https://doi.org/10.1016/j.clgc.2016.12.022 (e421) CrossRefPubMed

30.

Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H (2011) Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 60(5):1045–1054. https://doi.org/10.1016/j.eururo.2011.08.003 CrossRefPubMed

Titel: The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer
verfasst von: Ismail Selvi
Halil Basar
Numan Baydilli
Koza Murat
Ozlem Kaymaz
Publikationsdatum: 23.08.2019
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 11/2019
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02261-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

En bloc and two-lobe techniques for laser endoscopic enucleation of the prostate: retrospective comparative analysis of peri- and postoperative outcomes

Analysis of the clinical effect and long-term follow-up results of retroperitoneal laparoscopic ureterolithotomy in the treatment of complicated upper ureteral calculi (report of 206 cases followed for 10 years)

Intravesical stent position as a predictor of quality of life in patients with indwelling ureteral stent

Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis

The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial